Sign In
NASDAQ:BCLI
Brainstorm Cell Therapeutics Inc. Stock News
$1.68
-0.0600 (-3.45%)
At Close: Dec 02, 2024
NEW YORK , Dec. 2, 2024 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced that it wi
BrainStorm Cell Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update
04:30pm, Thursday, 14'th Nov 2024
Conference call planned for later in Q4 2024 to provide updates on NurOwn® program NEW YORK , Nov. 14, 2024 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of a
BrainStorm Cell Therapeutics and Pluri Partner to Support NurOwn® Phase 3b Trial Manufacturing
06:00am, Monday, 11'th Nov 2024
Memorandum of Understanding has been signed NEW YORK , Nov. 11, 2024 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative
BrainStorm Cell Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement
06:00am, Wednesday, 30'th Oct 2024
NEW YORK , Oct. 30, 2024 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, today announced that on October 29,
BrainStorm Cell Therapeutics Presented Positive Survival Data from NurOwn® Expanded Access Program at 2024 Annual NEALS Meeting
06:00am, Monday, 28'th Oct 2024
Biomarker data suggest ALS patients may benefit from longer-term treatment with NurOwn Poster highlighting design of planned Phase 3b NurOwn trial also presented NEW YORK , Oct. 28, 2024 /PRNewswire/
BrainStorm Cell Therapeutics to Provide Corporate Update on Phase 3b NurOwn® Trial at the 2024 Maxim Healthcare Virtual Summit
07:00am, Monday, 07'th Oct 2024
NEW YORK , Oct. 7, 2024 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced its partici
BrainStorm Cell Therapeutics Announces Presentations on NurOwn® at 2024 Annual NEALS Meeting
06:00am, Tuesday, 24'th Sep 2024
NEW YORK , Sept. 24, 2024 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, today announced the acceptance of
BrainStorm Cell Therapeutics Announces Second Quarter 2024 Financial Results and Provides Corporate Update
07:05am, Wednesday, 14'th Aug 2024
- Company reached alignment with the U.S. FDA on the Chemistry, Manufacturing, and Controls (CMC) aspects of its planned Phase 3b clinical trial for NurOwn® in ALS - SPA in place for Phase 3b NurO
BrainStorm Cell Therapeutics to Announce Second Quarter Results and Provide a Corporate Update
06:00am, Wednesday, 07'th Aug 2024
NEW YORK , Aug. 7, 2024 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced that it w
BCLI Update - Progress Supports Our 10x Plus Value Range Potential
08:30am, Wednesday, 24'th Jul 2024
ACF Equity Research FROM ACF EQUITY RESEARCH HEALTHCARE TEAM LONDON , July 24, 2024 /PRNewswire/ -- NASDAQ: BCLI READ ACF EQUITY RESEARCH'S UPDATE NOTE HERE READ ACF EQUITY RESEARCH'S RELATED TH
Brainstorm Cell Therapeutics Inc. (BCLI) Corporate Mid-Year Update on NurOwn Program (Transcript)
10:12am, Monday, 08'th Jul 2024
Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI ) Corporate Mid-Year Update on NurOwn Program July 8, 2024 8:00 AM ET Company Participants Joyce Lonergan - LifeSci Advisors Chaim Lebovits - President a
BrainStorm Cell Therapeutics to Provide Corporate Mid-Year Update on NurOwn Program
06:00am, Monday, 01'st Jul 2024
A conference call and webcast will be held Monday, July 8, at 8:00 a.m. Eastern Time NEW YORK , July 1, 2024 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of ad
BrainStorm Cell Therapeutics Announces Pricing of $4.0 Million Registered Direct Offering
09:15am, Thursday, 27'th Jun 2024
NEW YORK , June 27, 2024 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI) (the "Company"), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today ann
BrainStorm Cell Therapeutics Reaches Alignment with FDA on CMC Aspects of Phase 3b NurOwn® Clinical Trial
08:00am, Wednesday, 26'th Jun 2024
NEW YORK , June 26, 2024 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced it has r
BrainStorm Cell Therapeutics Announces Appointment of Haro Hartounian Ph.D. as Chief Operating Officer
06:00am, Thursday, 20'th Jun 2024
Appointment Completes Executive Readiness for Registrational Phase 3b ALS Study Launch NEW YORK , June 20, 2024 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer
